Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation

Byoung Jin Ha; Tae Im Kim; Seung Il Choi; R. Doyle Stulting; Dong Ho Lee; Hyun Soo Cho; Eung Kweon Kim

doi:10.1097/ICO.0b013e3181c3258a

Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation

Byoung Jin Ha, Tae Im Kim, Seung Il Choi, R. Doyle Stulting, Dong Ho Lee, Hyun Soo Cho, Eung Kweon Kim

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

Original language	English
Pages (from-to)	490-496
Number of pages	7
Journal	Cornea
Volume	29
Issue number	5
DOIs	https://doi.org/10.1097/ICO.0b013e3181c3258a
Publication status	Published - 2010 May

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1097/ICO.0b013e3181c3258a

Cite this

@article{f7b313d9ed1c4591800bc1d76fb45dba,

title = "Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation",

abstract = "Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.",

author = "Ha, {Byoung Jin} and Kim, {Tae Im} and Choi, {Seung Il} and Stulting, {R. Doyle} and Lee, {Dong Ho} and Cho, {Hyun Soo} and Kim, {Eung Kweon}",

year = "2010",

month = may,

doi = "10.1097/ICO.0b013e3181c3258a",

language = "English",

volume = "29",

pages = "490--496",

journal = "Cornea",

issn = "0277-3740",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation

AU - Ha, Byoung Jin

AU - Kim, Tae Im

AU - Choi, Seung Il

AU - Stulting, R. Doyle

AU - Lee, Dong Ho

AU - Cho, Hyun Soo

AU - Kim, Eung Kweon

PY - 2010/5

Y1 - 2010/5

N2 - Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

AB - Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation. Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps. Results: No measured between-group value showed a statistically significant difference. Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

UR - http://www.scopus.com/inward/record.url?scp=77951765347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951765347&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3181c3258a

DO - 10.1097/ICO.0b013e3181c3258a

M3 - Article

C2 - 20299970

AN - SCOPUS:77951765347

SN - 0277-3740

VL - 29

SP - 490

EP - 496

JO - Cornea

JF - Cornea

IS - 5

ER -

Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this